C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors
申请人:——
公开号:US05877197A1
公开(公告)日:1999-03-02
This invention is directed to novel (N-substituted)indole ICE/ced-3-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the treatment of ischemic injury.
Inhibition of inflammation using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
申请人:Idun Pharmaceuticals, Inc.
公开号:US20020123522A1
公开(公告)日:2002-09-05
The present invention provides methods for expanding and increasing survival of hematopoietic cell populations, for prolonging viability of an organ for transplantation, and enhancing bioproduction, using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors. Exemplary compounds useful in the methods of the invention are provided herein.
Inhibition of inflammation using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors
申请人:Idun Pharmaceuticals, Inc.
公开号:US06531467B2
公开(公告)日:2003-03-11
The present invention provides methods for expanding and increasing survival of hematopoietic cell populations, for prolonging viability of an organ for transplantation, and enhancing bioproduction, using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors. Exemplary compounds useful in the methods of the invention are provided herein.
C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors
申请人:IDUN Pharmaceuticals, Inc.
公开号:US05869519A1
公开(公告)日:1999-02-09
This invention is directed to novel (N-substituted)indole ICE-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.
Methods, compositions and kits for preserving antigenicity
申请人:——
公开号:US20030039661A1
公开(公告)日:2003-02-27
The present invention relates generally to programmed cell death and specifically to methods, compositions, and kits for preserving or enhancing antigenicity of markers associated with disease by utilizing inhibitors of apoptosis including interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors.